[go: up one dir, main page]

CN1037511A - 5-氯-3-氯磺酰基-2-噻吩羧酸酯的制备方法 - Google Patents

5-氯-3-氯磺酰基-2-噻吩羧酸酯的制备方法 Download PDF

Info

Publication number
CN1037511A
CN1037511A CN89102950A CN89102950A CN1037511A CN 1037511 A CN1037511 A CN 1037511A CN 89102950 A CN89102950 A CN 89102950A CN 89102950 A CN89102950 A CN 89102950A CN 1037511 A CN1037511 A CN 1037511A
Authority
CN
China
Prior art keywords
chlorine
formula
iron
method comprises
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN89102950A
Other languages
English (en)
Other versions
CN1028101C (zh
Inventor
汉斯·彼得·瓦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nikelaide Austria Co.,Ltd.
Nikemude Denmark Corp.
Original Assignee
Cl Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cl Pharmaceuticals filed Critical Cl Pharmaceuticals
Publication of CN1037511A publication Critical patent/CN1037511A/zh
Application granted granted Critical
Publication of CN1028101C publication Critical patent/CN1028101C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

在活性铁存在条件下,通过氯化制备5-氯-3- 氯磺酰基-2-噻吩羧酸酯的方法。

Description

本发明是关于5-氯-3-氯磺酰基-2-噻吩羧酸酯的制备方法。
5-氯-3-氯磺酰基-2-噻吩羧酸烷基酯(5-CCT)是制备药理活性物质的中间体。例如,US-PS4,801,591中叙述了用5-CCT作原料制备的降血脂药物。US-PS4,180,662中介绍的制备6-氯-4-羟基-2-甲基-3-(2-吡啶氨基甲酰基)-2H-噻吩并(2,3-e)1,2-噻吩1,1-二氧化物(chlorotenoxicam,一种抗风湿药)的方法也可以采用5-CCT作原料。
在GB-A2,159,156中,叙述了一种制备被甲基或卤素取代的3-氯磺酰基-2-噻吩羧酸烷基酯的制备方法。此方法中,要先把不易得到的5-氯-3-氨基-2-噻吩羧酸烷基酯重氮化,再使所得重氮产物与SO2反应得到上述含硫氯化物。但这种方法复杂费时,而且产率不高。
本发明涉及制备式Ⅰ的5-氯-3-氯磺酰基-2-噻吩羧酸酯的方法,式Ⅰ中R代表C1-C4烷基。
该方法的特征是,在活性铁存在下,用氯气将式Ⅱ化合物氯化。式Ⅱ中R的含义同上。
Figure 891029508_IMG4
铁的活化方法是先将粉末或碎屑状的金属铁悬浮于反应条件下显惰性的有机溶剂中,金属铁的用量是每mol(摩尔)化合物Ⅱ0.1-1.0mol,最好是0.2~0.4mol,有机溶剂例如有二氯甲烷、四氯化碳或它们的混合物,但最好是二氯甲烷,有机溶剂的量为0.5~51(升),最好是1-31。然后在大约10-50℃,最好是24-28℃,并在剧烈搅拌条件下,按每摩尔铁100-500g,最好为200-300g的量向金属铁悬浮液中通入氯气将铁活化。通氯气的时间是1-5小时,最好是2-3小时。
另一种活化方法是,先把同上述情况大约等量的铁放入反应烧瓶中,然后在氯气气氛中,静置混合物12-48小时,最好是24小时。但在溶剂悬浮液中进行铁的活化比较好。
如果铁是悬浮在溶剂中活化的,那么氯化3-氯磺酰基-2-噻吩羧酸烷基酯(CT)时,是将CT溶解在悬浮金属铁时所用同样的溶剂或混合溶剂中。每mol    CT约使用0.3-51,最好是0.5-11溶剂。然后迅速将所得溶液与铁的悬浮液相混合。在大约20-50℃,最好在30-32℃温度和搅拌条件下,按每小时和每mol    CT5-50g,最好是15-35g的量通入氯气将CT氯化。对反应过程进行分析跟踪,最好用气相色谱法。在50~70%,最好是62-65%的一氯化物生成后,把反应混合物倒入冰水中,分离两相,干燥并蒸发有机相。
如果铁是在氯气气氛中活化的,则最好将CT溶解在2-41上述一种溶剂或混合溶剂中,氯化过程的其余部分同上所述。所用溶剂总量对两种活化方法是相同的。
5-CCT粗品的提纯可用一般方法进行,例如重结晶、柱色谱和分配色谱以及萃取等。从异丙醚中重结晶比较好。
氯化的初始化合物CT在文献中是已知的。例如,在US-PS4,028,373中叙述了CT的制法。
实例
5-氯-3-氯磺酰基-2-噻吩羧酸甲酯
把96g铁粉(1.71mol)(Baker,用H2还原,纯度不小于96%)悬浮于盛在一个201四颈烧瓶中的121绝对二氯甲烷中。在剧烈搅拌条件下,2-3小时内,向悬浮液中通入440g氯气,此过程中温度在24和28℃之间。再把1.44kg(5.98mol)3-氯磺酰基噻吩羧酸甲酯溶于51绝对二氯甲烷并迅速加到上面的悬浮液中。然后在30-32℃及搅拌下每小时通入100~200g氯气,反应过程用气相色谱法进行监测。当62-65%的一氯化物生成后,将反应混合物倒入241冰水中并剧烈搅拌15分钟。分离两相后,干燥处理有机相,并在40℃浴温度下真空蒸发残余物。
用1.51异丙醚将剩余物溶解,过滤,把滤液冷却至-30~-35℃。用一氯化物引晶后,让滤液结晶大约15-30分钟。吸滤出晶体,在-30℃用0.51异丙醚冲洗,在真空烘箱中于25℃进行干燥。
产量:800g一氯化物(48.7%)
气相色谱:95%是一氯化物,其余是未氯化及二氯化产物。
熔点:50~52℃

Claims (9)

1、制备式Ⅰ的5-氯-3-氯磺酰基-2-噻吩羧酸酯的方法,
Figure 891029508_IMG1
式Ⅰ中R代表C1-C4烷基,该方法包括:用氯气活化金属铁,以及在活性铁存在下通入氯气,将式Ⅱ化合物氯化,
Figure 891029508_IMG2
式Ⅱ中R含义同上。
2、按照权利要求1的方法,该方法包括:在氯气气氛中用氯气活化金属铁。
3、按照权利要求1的方法,该方法包括:在氯气气氛中活化金属铁12至48小时。
4、按照权利要求1的方法,该方法包括:在氯气气氛中,活化金属铁24小时。
5、按照权利要求1的方法,该方法包括:用氯气在溶剂悬浮液中将金属铁活化,对于每mol式Ⅱ化合物,将0.1至1.0mol金属铁悬浮在0.5至51反应条件下显惰性的有机溶剂或其混合物中,每mol铁通氯气100至500g,通气时间为1~5小时。
6、按照权利要求1的方法,该方法包括:按每摩尔式Ⅱ化合物0.2~0.4mol金属铁的比例,把铁悬浮在1-31二氯甲烷或四氯化碳或它们的混合物中,再按每mol  200-300g氯气的比例,向悬浮液中通氯气活化2-3小时。
7、按照权利要求1的方法,该方法包括:在同样的溶剂或混合溶剂中进行铁的活化和式Ⅱ化合物的氯化。
8、按照权利要求1的方法,该方法包括:在20-50℃温度下,按每小时和每mol式Ⅱ化合物用5-50g氯气的条件,把式Ⅱ化合物通氯气氯化,直到生成50-70%的一氯化物,然后把反应混合物倒入冰水中。
9、按照权利要求1的方法,该方法包括:在30-32℃下,按每小时和每mol式Ⅱ化合物用15-35g氯气的条件,把式Ⅱ化合物通氯气氯化,直到生成62-65%的一氯化物,然后把反应混合物倒入冰水中。
CN89102950A 1988-05-02 1989-04-29 5-氯-3-氯磺酰基-2-噻吩羧酸酯的制备方法 Expired - Lifetime CN1028101C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0112388A AT390060B (de) 1988-05-02 1988-05-02 Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern
ATA1123/88 1988-05-02

Publications (2)

Publication Number Publication Date
CN1037511A true CN1037511A (zh) 1989-11-29
CN1028101C CN1028101C (zh) 1995-04-05

Family

ID=3507085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN89102950A Expired - Lifetime CN1028101C (zh) 1988-05-02 1989-04-29 5-氯-3-氯磺酰基-2-噻吩羧酸酯的制备方法

Country Status (28)

Country Link
US (1) US5138072A (zh)
EP (1) EP0340472B1 (zh)
JP (1) JP2785132B2 (zh)
KR (1) KR970000685B1 (zh)
CN (1) CN1028101C (zh)
AT (2) AT390060B (zh)
AU (1) AU614058B2 (zh)
CA (1) CA1333177C (zh)
CS (1) CS275851B6 (zh)
CY (1) CY1756A (zh)
DD (1) DD283818A5 (zh)
DE (1) DE58905010D1 (zh)
DK (1) DK172655B1 (zh)
EG (1) EG20136A (zh)
ES (1) ES2058372T3 (zh)
FI (1) FI86062C (zh)
GR (1) GR3008623T3 (zh)
HK (1) HK128193A (zh)
HU (1) HU202518B (zh)
IL (1) IL89902A0 (zh)
MY (1) MY103874A (zh)
NO (1) NO171912C (zh)
NZ (1) NZ228772A (zh)
PH (1) PH27581A (zh)
SA (1) SA89100027B1 (zh)
SU (1) SU1704632A3 (zh)
YU (1) YU48507B (zh)
ZA (1) ZA892791B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4232417A1 (de) * 1992-09-28 1994-03-31 Bayer Ag Substituierte Thienylsulfonylharnstoffe
DE19540737A1 (de) * 1995-11-02 1997-05-07 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
CN106434833A (zh) * 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
WO2007062213A2 (en) * 2005-11-23 2007-05-31 Housey Pharmaceuticals Inc Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
CN116693498B (zh) * 2023-05-30 2024-01-30 湖北广济医药科技有限公司 一种利用连续流动反应合成5-氯-3-(氯磺酰基)-2-噻吩羧酸甲酯的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE698778C (de) * 1934-11-11 1941-07-10 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von organischen Monochlor- oder Monobromverbindungen
DE2227439B2 (de) * 1972-06-06 1977-05-05 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Chlorierung oder bromierung phenolischer verbindungen
DE2534689B2 (de) * 1974-09-16 1979-03-01 Basf Ag, 6700 Ludwigshafen 23-Dihydro-3-oxo-thieno-isothiazol-1,1-dioxide
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
FR2564834A1 (fr) * 1984-05-24 1985-11-29 Du Pont Procede de preparation de 3-chlorosulfonylthiophene-2-carboxylate d'alcoyle
FI862513A (fi) * 1985-07-04 1987-01-05 Chemie Linz Ag Nya tieno-1,2-tiazolderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat.
DE3785694T2 (de) * 1986-05-13 1993-09-16 Seitetsu Kagaku Co Ltd Thiophenderivate und verfahren zu ihrer herstellung.

Also Published As

Publication number Publication date
CY1756A (en) 1994-06-03
ES2058372T3 (es) 1994-11-01
DK172655B1 (da) 1999-04-12
FI86062B (fi) 1992-03-31
AU614058B2 (en) 1991-08-15
DK211189D0 (da) 1989-05-01
GR3008623T3 (zh) 1993-10-29
KR890017240A (ko) 1989-12-15
EG20136A (en) 1997-07-31
EP0340472B1 (de) 1993-07-28
NO891679L (no) 1989-11-03
HK128193A (en) 1993-11-26
FI86062C (fi) 1992-07-10
NO171912B (no) 1993-02-08
HUT49869A (en) 1989-11-28
YU48507B (sh) 1998-09-18
JPH01313474A (ja) 1989-12-18
US5138072A (en) 1992-08-11
YU81089A (en) 1990-06-30
EP0340472A1 (de) 1989-11-08
DD283818A5 (de) 1990-10-24
CN1028101C (zh) 1995-04-05
CS275851B6 (en) 1992-03-18
CA1333177C (en) 1994-11-22
AT390060B (de) 1990-03-12
FI892051A0 (fi) 1989-04-28
ZA892791B (en) 1989-12-27
NZ228772A (en) 1990-09-26
MY103874A (en) 1993-09-30
ATA112388A (de) 1989-08-15
DE58905010D1 (de) 1993-09-02
NO171912C (no) 1993-05-19
AU3380189A (en) 1989-11-02
HU202518B (en) 1991-03-28
ATE92056T1 (de) 1993-08-15
PH27581A (en) 1993-08-18
DK211189A (da) 1989-11-03
KR970000685B1 (ko) 1997-01-18
SU1704632A3 (ru) 1992-01-07
FI892051A (fi) 1989-11-03
SA89100027B1 (ar) 2003-04-09
NO891679D0 (no) 1989-04-24
IL89902A0 (en) 1989-12-15
JP2785132B2 (ja) 1998-08-13

Similar Documents

Publication Publication Date Title
CN1028101C (zh) 5-氯-3-氯磺酰基-2-噻吩羧酸酯的制备方法
DE69306595T2 (de) Regioselektive synthese von 4-chlor-2-thiophencarbonsäure
CN107602651A (zh) 一种去氢表雄酮中间体及去氢表雄酮的制备方法
AU592435B2 (en) Method of preparation of dithiocarbamate complexes of molybdenum
KR930004054B1 (ko) N-포르밀-α-L-아스파틸-L-페닐알라닌 메틸 에스테르의 제조방법
JPH02501748A (ja) 4,4’‐ジブロモジフェニルエーテルの製造法
JPS6249261B2 (zh)
CN103012437A (zh) 抗菌药物头孢西丁酸的制备方法
CN115433194B (zh) 一种六氢-3aH-呋喃[2,3-c]吡咯-3a-羧酸甲酯类衍生物的合成方法
US4190724A (en) Process for 3-exomethylenecepham sulfoxides
CN115819298A (zh) 一种对甲苯磺酰甲基异腈的制备方法及其应用
KR20010029563A (ko) 펜타아세틸-β-D-글루코피라노즈의 제조 방법
DE3782698T2 (de) 5-fluoruridin-derivat und dessen herstellung.
CN106831648A (zh) 二氮嗪的合成方法
JPH0512338B2 (zh)
KR840000115B1 (ko) 카바졸 유도체의 제조방법
EP0236383B1 (en) Method for preparing 6beta-halopenicillanic acids and salts thereof
DE4313664C2 (de) N-Fluormethansulfonimid, Verfahren zu seiner Herstellung sowie dessen Verwendung
DE2460477A1 (de) Verbessertes verfahren zur herstellung von 6-alkoxy-substituierten penicillinen
CN105906604B (zh) 一种2‑噻吩乙酸的合成方法
CN106632001A (zh) 一种4‑(溴乙酰基)吡啶氢溴酸盐的制备方法
Hatanaka et al. Synthesis of tricyclic cephalosporins
JP2513222B2 (ja) 新規ピリミジン誘導体
JPH02157239A (ja) 3,5―ジアルキル―4―ヒドロキシベンジル―置換された芳香族の製法
CN116640152A (zh) 一种苯并噻吩并吡啶类衍生物及合成方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C53 Correction of patent of invention or patent application
COR Change of bibliographic data

Free format text: CORRECT: PATENTEE; FROM: NICOLETER AUSTRIA CO., LTD. TO: NICOMUDE DENMARK CO.,LTD.

Free format text: CORRECT: PATENTEE; FROM: HOUGHENLUN· NICAMUD MEDICINE STOCK CO., LTD. TO: NICOLETER AUSTRIA CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Roskilde

Patentee after: Nikemude Denmark Corp.

Address before: Linz, Austria

Patentee before: Nikelaide Austria Co.,Ltd.

Patentee after: Nikelaide Austria Co.,Ltd.

Patentee before: Havnn Nikamed pharmaceutical AG

C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term